Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders

Vivian A. Paschoal and Da Young Oh

Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

ABSTRACT

G Protein-coupled receptor 120 (GPR120; fatty acid receptor 4, FFAR4) and PPARγ agonists both lead to anti-inflammatory and insulin sensitizing effects despite signalling through distinct pathways. We recently reported the overarching idea that these two pathways are interactive. Specifically, treatment of obese mice with the PPARγ agonist rosiglitazone (a thiazolidinedione, TZD) in combination with the GPR120 agonist compound A synergistically improves glucose tolerance and insulin sensitivity. We have deconvoluted the mechanisms underlying this feed-forward effect in the study. Taken together, our study shows that low dose TZD administration, in combination with GPR120 agonists, produces additive beneficial effects on glucose tolerance and insulin sensitivity without the undesirable adverse effects of TZD. Our study suggests potential value of combination PPARγ and GPR120 agonists to treat metabolic disease.

The discovery that adipose tissue of obese mice and humans is infiltrated with macrophages provided a major mechanistic advance in our understanding of how obesity promotes inflammation [1,2]. Macrophages are a major source of proinflammatory cytokines that can decrease insulin sensitivity through a paracrine and potentially an endocrine mechanism. Over the past decade, we and many other groups have assessed the pathogenic role of macrophages as an initiator of insulin resistance. Specifically, we found that G protein-coupled receptor 120 (GPR120), upon activation by its ligand omega-3 fatty acids (ω3-FAs, including DHA and EPA) produce robust anti-inflammatory, insulin sensitizing effects both in vivo and in vitro [3]. Since the large amount of ω3-FAs that would have to be consumed to sustain GPR120 activation is not practical, various high-affinity small molecule GPR120 agonists have been developed for potential clinical use by the pharmaceutical industry. We have identified a high-affinity, selective GPR120 agonist (compound A; CpdA) that exerts potent anti-inflammatory effects on macrophages in vitro and in obese mice in a GPR120 dependent manner [4]. GPR120 agonist treatment of HFD/obese mice enhanced anti-inflammatory signalling, glucose tolerance, and insulin sensitivity while decreasing hyperinsulinemia and hepatic steatosis [3,4]. This suggests that GPR120 agonists could emerge as a new insulin-sensitizing agent for T2D treatment.

TZDs (thiazolidinedione), such as rosiglitazone and pioglitazone, are effective therapeutic agents for insulin resistance in humans. However, they can cause adverse effects such as oedema [5–7], weight gain [8,9], heart failure [10–12], bone loss [13,14], and apparently certain cancers [15,16]. While the exact mechanisms of TZD-induced insulin sensitization are not fully understood, these agents act through PPARγ, which has been extensively reviewed elsewhere [17–19]. Therefore, downstream targets of PPARγ are believed to mediate insulin sensitization.

The key idea of our recent paper [20] is that TZDs cause insulin sensitization by acting through PPARγ and its target genes. In addition, GPR120 agonists cause anti-inflammation and insulin sensitivity through a GPR120 signalling pathway that involves β arrestin-2 and Gγ11 coupling. Since these two classes of agonists cause insulin sensitization through distinct mechanisms, we wondered if their co-administration may provide an additive effect. Our hyperinsulinemic-euglycemic clamp studies showed that in HFD-fed mice, the insulin-sensitizing effects of rosiglitazone (Rosi) on WT mice was substantially attenuated in the GPR120 KO mice. This was the first clue that the two pathways interact. We then set out to do multiple treatment studies at different doses of
rosiglitazone to assess the potential of additivity with GPR120 agonist in vivo. Using the GPR120 agonist compound A (CpdA), we see a robust additivity when combined with Rosi treatment in HFD-fed WT mice but not in GPR120 KO mice. Importantly, we established the lowest dose of Rosi that gives a detectable albeit weak improvement of glucose tolerance and insulin sensitivity. When this ‘minimal’ dose of Rosi is co-administered with a GPR120 agonist, we get full insulin sensitization and improved glucose tolerance much like ‘maximal’ dose of Rosi. This demonstrates the additivity of these mechanisms.

To address the mechanisms for this additivity, we conducted detailed in vivo physiologic as well as cellular and molecular studies. From the physiologic point of view, we generated adipocyte (AKO) and macrophage specific (MKO) GPR120 knockout models. These two models, along with other in vivo data using a GPR120 agonist (CpdA treatment) enabled us to identify an in vivo mechanistic basis for the combined effects of PPARγ and GPR120 agonists. The tissue-specific KO mouse models demonstrate the concept that the insulin sensitizing effects of the GPR120 agonists are primarily mediated through their antiinflammatory actions in macrophages while adipocytes play a minor role. This is contrast to Rosi, which acts primarily on adipocytes. In other words, the additivity in vivo from a whole system point of view arises by complementing the effect of CpdA on macrophages with that of Rosi on adipocytes (Figure 1). We also found that CpdA has direct insulin sensitizing effects in adipocytes, resulting in an additional layer of additivity from a cell autonomous point of view.

Our studies show that GPR120 is a PPARγ target gene, and its induction by Rosi enables TZDs to potentiate the effects of GPR120 agonist. Conversely, the GPR120 agonist stimulates the production of 15d-PGJ2, which we established as an endogenous PPARγ agonist in adipocytes that stimulates the transactivation of PPARγ target genes including GPR120, providing another layer of feed-forward, and NCoR dissociation, CDK5 dissociation, etc. Although 15d-PGJ2 can clearly stimulate PPARγ, its physiological and pharmacological relevance has been debated [21,22]. For example, the concentrations required to activate PPARγ are generally reported in the μM range, while many other endogenous prostaglandins are effectively act at low nM concentrations. Consistent with this, we were not able to detect 15d-PGJ2 in mouse plasma. However, 15d-PGJ2 acts intracellularly to activate PPARγ, in contrast to other prostaglandins that principally act as extracellular ligands of cell surface receptors. Thus, future studies on the role of 15d-PGJ2 as an endogenous PPARγ activator will be of interest particularly related to bioactive intracellular and microenvironmental concentrations. As an additional mechanism, stimulation of GPR120 with CpdA maintains PPARγ S273 in the unphosphorylated state [20], which is more active than the phosphorylated form [23–25]. The mechanism for this is that in response to extracellular CpdA, cell-surface GPR120 recruits β arrestin-2, leading to endo-cytic internalization of the two proteins. The internalized β arrestin-2 in turn colocalizes with and sequesters ERK (the main kinase for S273) in the cytosol, preventing its nuclear translocation and phosphorylation of PPARγ S273. Together these cellular mechanisms outline a positive reinforcing interaction between these two signalling systems within adipocytes.

In summary, the overall additivity is explained by overarching mechanism (Figure 1):

1. In vivo, Effects on macrophages (GPR120) and adipocytes (GPR120 + PPARγ) combining to cause enhanced insulin sensitivity.
2. Adipocyte-autonomous additivity between GPR120 and PPARγ signalling.

Beyond enhancing therapeutic efficacy, combination treatment may also provide the benefit of minimizing side effects. Specifically, although TZDs have been FDA approved for many years, their clinical use is compromised by well-known side effects particularly weight gain and oedema. We find that...
combination treatment with GPR120 agonists and Rosi prevents the effects of Rosi to cause weight gain and oedema, even if we used maximal dose of Rosi. We do not know the mechanisms for this, but they are consistent across many cohorts of mice. Furthermore, because we find additive combinatorial efficacy on insulin sensitivity, we were able to titrate down Rosi to a ‘minimal’ dose that does not lead to body weight gain or oedema.

Whether this benefit extends to other side effects of TZDs like bone loss is currently unknown.

Taken together, we propose that simultaneous targeting of GPR120 and PPARγ may have clinical value. The mechanisms we defined to provide a compelling explanation for the in vivo additivity, which leads to greater efficacy and less side effects.

Disclosure statement
The authors declare no competing financial interests.

Funding
This work was supported by grants from the NIH (R01 DK108773 to D.Y.O.), the American Heart Association (14SDG19880020 to D.Y.O.), and the American Diabetes Association Minority Postdoctoral Fellowship (1-18-PMF-030 to V.A.P.).

ORCID
Da Young Oh http://orcid.org/0000-0003-0687-6479

References
[1] Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808.
[2] Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
[3] Oh Dy, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–698.
[4] Oh Da y, Walenta E, Akiyama TE, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014;20:942–947.
[5] Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29:510–514.
[6] Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodialilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007;82:275–281.
[7] Nesto RW, Bell D,Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263.
[8] Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115 (Suppl 8A):425–485.
[9] Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011;17:618–622.
[10] Duan SZ, Ivashchenko CY, Russell MW, et al. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptorgamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372–379.
[11] Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a metaanalysis of randomised clinical trials. Lancet. 2007;370:1129–1136.
[12] Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791–2801.
[13] Bray GA, Smith SR, Banerji MA, et al. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab. 2013;15:931–937.
[14] Colhoun HM, Livingstone SJ, Looker HC, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929–2937.
[15] Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.
[16] Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–1962.
[17] Ahmadian M, Suh JM, Hah N, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557–566.
[18] Soccio RE, Chen ER, Lazaro MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573–591.
[19] Wahl W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351–363.
[20] Paschoal VA, Walenta E, Talukdar S, et al. Positive reinforcing mechanisms between GPR120 and PPARgamma modulate insulin sensitivity. Cell Metab. 2020;31:1173–1188 e1175.
[21] Bell-Parikh LC, Ide T, Lawson JA, et al. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest. 2003;112:945–955.
[22] Powell WS. 15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product? J Clin Invest. 2003;112:828–830.

[23] Banks AS, McAllister FE, Camporez JP, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature. 2015;517:391–395.

[24] Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesitylinked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466:451–456.

[25] Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477–481.